Acquired by Asahi Kasei in Oct 2024
CALT - Calliditas Therapeutics AB (publ)
NASDAQ
->
Healthcare
->
Biotechnology
Stockholm,
Sweden
Type: Equity
CALT price evolution
CALT
| (in millions $) | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $797.28 | $810.32 | $973.73 | $786.88 |
| Short term investments | ||||
| Net receivables | $222.59 | $182.82 | $196.67 | $130.53 |
| Inventory | $40.16 | $29.3 | $20.43 | $16 |
| Total current assets | $1154.46 | $1098.9 | $1275.15 | $1036.01 |
| Long term investments | ||||
| Property, plant & equipment | $59.36 | $65.38 | $54.24 | $55.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1747.2 | $1688.3 | $1859.24 | $1611.89 |
| Current liabilities | ||||
| Accounts payable | $151.01 | $101.38 | $100.56 | $67.16 |
| Deferred revenue | ||||
| Short long term debt | $12.54 | |||
| Total current liabilities | $429.78 | $408.17 | $407.14 | $344.71 |
| Long term debt | $1008.27 | $1016.62 | $966.6 | $770.16 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1640.42 | $1568.14 | $1524.44 | $1259.46 |
| Shareholders' equity | ||||
| Retained earnings | -$2305.57 | |||
| Other shareholder equity | $104.39 | $120.15 | $332.42 | $350.05 |
| Total shareholder equity | $106.79 | $120.15 | $334.81 | $352.44 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $973.73 | $1249.09 | $955.51 | $996.3 |
| Short term investments | ||||
| Net receivables | $196.67 | $88.72 | $11.34 | $22.8 |
| Inventory | $20.43 | $3.65 | $0.89 | |
| Total current assets | $1275.15 | $1412.2 | $1012.77 | $1036.85 |
| Long term investments | $0 | |||
| Property, plant & equipment | $54.24 | $31.92 | $39.61 | $5.41 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $51.19 | |||
| Total investments | ||||
| Total assets | $1859.24 | $1952.97 | $1459.91 | $1506.45 |
| Current liabilities | ||||
| Accounts payable | $100.56 | $160.4 | $67.97 | $53.83 |
| Deferred revenue | ||||
| Short long term debt | $12.54 | $10.37 | $9.59 | |
| Total current liabilities | $407.14 | $325.23 | $135.45 | $105.62 |
| Long term debt | $966.6 | $728.82 | $189.16 | $0.88 |
| Total noncurrent liabilities | $15.75 | |||
| Total debt | ||||
| Total liabilities | $1524.44 | $1186.71 | $451.63 | $250.15 |
| Shareholders' equity | ||||
| Retained earnings | -$2305.57 | -$1827.01 | -$1418.35 | -$918.6 |
| Other shareholder equity | $5.2 | $0 | -$35.2 | -$6.09 |
| Total shareholder equity | $334.81 | $766.26 | $1008.28 | $1210.49 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $559.78 | $295.48 | $451.56 | $294.59 |
| Cost of revenue | $53.45 | $14.01 | $14.92 | |
| Gross Profit | $506.33 | $281.47 | $429.26 | $279.67 |
| Operating activities | ||||
| Research & development | $120.72 | $150.61 | $106.68 | $179.91 |
| Selling, general & administrative | $419.82 | $342.16 | $293.17 | $259.17 |
| Total operating expenses | $591.28 | $499.31 | $409.8 | $454.16 |
| Operating income | -$31.5 | -$203.83 | -$159.57 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $4.82 | -$1.16 | $4.11 | $4.28 |
| Interest expense | -$11.16 | -$56.02 | -$4.51 | |
| Net income | ||||
| Net income | -$47.48 | -$246.16 | -$18.37 | -$168.36 |
| Income (for common shares) | -$47.48 | -$246.16 | -$18.37 | -$168.36 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1206.89 | $802.88 | $229.35 | $0.87 |
| Cost of revenue | $60.46 | $15.2 | ||
| Gross Profit | $1146.42 | $787.68 | $229.35 | $0.87 |
| Operating activities | ||||
| Research & development | $502.22 | $414.75 | $357.49 | $241.37 |
| Selling, general & administrative | $1060.73 | $774.66 | $390.23 | $133.61 |
| Total operating expenses | $1579.94 | $1201.75 | $753.8 | $374.98 |
| Operating income | -$373.06 | -$398.87 | -$524.46 | -$374.1 |
| Income from continuing operations | ||||
| EBIT | -$524.46 | -$374.1 | ||
| Income tax expense | $9.17 | $2.85 | -$3.84 | $0.36 |
| Interest expense | -$83.96 | -$32.8 | -$0.39 | |
| Net income | ||||
| Net income | -$466.18 | -$412.27 | -$500.29 | -$433.49 |
| Income (for common shares) | -$466.18 | -$412.27 | -$500.29 | -$433.49 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$47.48 | -$246.16 | -$168.36 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$7.04 | -$198.2 | -$62.53 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.1 | -$3.86 | -$13.74 | -$7.42 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | |||
| Net borrowings | -$4.06 | -$5.47 | -$2.89 | |
| Total cash flows from financing | -$4.05 | -$5.47 | $199.65 | -$2.89 |
| Effect of exchange rate | -$26.61 | |||
| Change in cash and equivalents | -$13.04 | -$163.42 | -$275.36 | -$79.3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$466.18 | -$412.27 | -$500.29 | -$433.49 |
| Operating activities | ||||
| Depreciation | $12.91 | $2.82 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$434.66 | -$311.35 | -$461.59 | -$309.18 |
| Investing activities | ||||
| Capital expenditures | -$2.51 | |||
| Investments | -$0.01 | |||
| Total cash flows from investing | -$13.74 | -$5.14 | -$24.34 | -$172.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $95.12 | |||
| Net borrowings | $226.28 | $482.13 | $193.95 | -$3.97 |
| Total cash flows from financing | $199.65 | $575.99 | $435.16 | $768.56 |
| Effect of exchange rate | $39.51 | $9.97 | -$44.01 | |
| Change in cash and equivalents | -$275.36 | $293.59 | -$40.8 | $242.76 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 27.00M |
| Revenue | $1.60B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$480.37M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 0.09 |
| Cash/Share | 29.53 |
| EPS | -$17.79 |
|---|---|
| ROA | -27.82% |
| ROE | -210.18% |
| Debt/Equity | 4.55 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.69 |
| Quick ratio | 2.59 |